Title:
Theranostic liposomes for cancer diagnosis and treatment: Current development and pre-clinical success

dc.contributor.authorMadaswamy S Muthu
dc.contributor.authorSi-Shen Feng
dc.date.accessioned2026-02-07T05:42:49Z
dc.date.issued2013
dc.description.abstractLiposomes are one of the effective drug delivery systems that are developed based on the nanotechnology concept. Liposomal formulation is the first nanomedicine approved by the US FDA for clinical application. Recently, the marketed liposomes and stealth liposomes have made impact for cancer therapy. In addition, a few receptor-targeted liposome products have been in different phases of clinical trials, which are yet to be marketed. In the present editorial, the advantages of vitamin E TPGS-coated liposomes over the currently available PEG-coated liposomes will be described and their great potentials for nanotheranostics for cancer imaging and therapy will be covered. © 2013 Informa UK, Ltd.
dc.identifier.doi10.1517/17425247.2013.729576
dc.identifier.issn17447593
dc.identifier.urihttps://doi.org/10.1517/17425247.2013.729576
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/25501
dc.subjectCancer chemotherapy
dc.subjectDiagnosis
dc.subjectFolate targeting
dc.subjectNanotheranostics
dc.subjectQuantum dots
dc.subjectStealth liposomes
dc.subjectVitamin E TPGS
dc.titleTheranostic liposomes for cancer diagnosis and treatment: Current development and pre-clinical success
dc.typePublication
dspace.entity.typeReview

Files

Collections